Abstract
Cancer is the second leading cause of morbidity and mortality globally. A variety of effective regimens are available for the treatment of different cancers, however, there is still a need for the development of safe and effective broad-spectrum anti-cancer agent(s). Towards this, amino acid-depleting enzymes have proven to be effective in the treatment of certain auxotrophic cancers. In this review, we have briefly discussed arginine metabolism and arginine depletion as an effective strategy in the treatment of arginine-auxotrophic cancers. We have discussed the latest events in the field of development of recombinant human Arg I (rh-Arg I) for different cancers, current status of development of various arginine-depleting enzymes, their limitations, and potential approaches to overcome these limitations. Keywords: Auxotrophy, arginine metabolism, arginine deiminase, arginase, fusion protein technology Cite this Article Sayantap Datta, Priyanka Kawathe, Snehal Sainath Jawalekar, Abhay H Pande. Human Arginase I (Arg I)—A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead. Research & Reviews: Journal of Oncology and Hematology . 2020; 9(3): 23–35p. DOI: https://doi.org/10.37591/rrjooh.v9i3.2312
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Research & Reviews: Journal of Oncology and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
